Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Influenza A/H3N2 hemagglutinin antigen (HA) is a major surface glycoprotein of the influenza A virus subtype H3N2, playing a critical role in the initiation of viral infection. It functions as a class I viral fusion protein, consisting of two subunits, HA1 and HA2, which form a homotrimer on the viral envelope. The HA1 subunit mediates the attachment of the virus to host cell surface receptors containing alpha-2,6-linked sialic acid, while the HA2 subunit facilitates the fusion of the viral envelope with the endosomal membrane under low-pH conditions. Because of its essential role in viral entry, HA is the primary target of the host neutralizing antibody response and the immunodominant component of seasonal influenza vaccines. It is also a key target for antiviral drug development, including small-molecule fusion inhibitors like umifenovir (Arbidol) and investigational monoclonal antibodies like diridavumab, which aim to block viral entry or membrane fusion. However, the high rate of antigenic drift and the emergence of egg-adaptive mutations during vaccine production present significant challenges to maintaining vaccine and therapeutic efficacy.
Inhibition of viral entry and membrane fusion by binding to the hemagglutinin protein, preventing the low pH-induced conformational change required for fusion of the viral envelope with the host endosomal membrane.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Influenza A/H3N2 hemagglutinin antigen (HA).